Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: A prospective multicenter cohort study
Key result
In patients with atrial fibrillation or mechanical heart valves, a subtherapeutic INR was associated with a 1.40% incidence of thromboembolic events (95% CI 0.68-2.86%) within 90 days.
Why the study?
What is the incidence of thromboembolic events in patients with high-risk atrial fibrillation or mechanical heart valves who have a subtherapeutic INR?
Population
501 consecutive patients with a history of stable anticoagulation but with a subtherapeutic INR, including…
Design
Cohort
Follow-up
90 days
Authors
Discussion
Loading...
Member takes
Implication
Subtherapeutic INR was associated with TE events in high-risk AF/MHV; leaves open optimal management pending randomized confirmation.
Study Design
Type
Cohort (n=501)
Multicenter
Yes
Structured PICO
What is the incidence of thromboembolic events in patients with high-risk atrial fibrillation or mechanical heart valves who have a subtherapeutic INR?
P
Population
501 patients with mechanical heart valves or high-risk atrial fibrillation (CHADS2 score ≥3) and a subtherapeutic INR, followed for 90 days.
E
Exposure
Subtherapeutic INR exposure (with or without low-molecular weight heparin [LMWH] bridging therapy)
O
Outcome
Incidence of objectively confirmed thromboembolic events (TE) and major bleeding events within 90 days after the index INRhard clinical
Patients with high-risk AF or mechanical heart valves experiencing a subtherapeutic INR have a non-negligible risk of thromboembolic events (1.40% within 90 days), all occurring within 14 days.
Cite This Study
Dentali et al. (2012) conducted a cohort in Atrial fibrillation or mechanical heart valves with subtherapeutic INR (n=501). Subtherapeutic international normalized ratio (INR) was evaluated on Incidence of objectively confirmed thromboembolic events (TE) and major bleeding events within 90 days (95% CI 0.68-2.86). In patients with atrial fibrillation or mechanical heart valves, a subtherapeutic INR was associated with a 1.40% incidence of thromboembolic events (95% CI 0.68-2.86%) within 90 days.